XML 32 R21.htm IDEA: XBRL DOCUMENT
v3.24.0.1

Note 15 - Equity Incentive Plans | 6 Months Ended
--- | ---
Dec. 31, 2023
Notes to Financial Statements |
Share-Based Payment Arrangement [Text Block] | Note 15 - Equity Incentive Plans 2023 Equity Incentive Plan. On May 18, 2023, the Company’s stockholders approved the Aytu BioPharma, Inc. 2023 Equity Incentive Plan (the “2023 Equity Incentive Plan”). Prior to the Company’s adoption of the 2023 Equity Incentive Plan, the Company awarded equity incentive grants to its directors and employees under the Aytu BioScience, Inc. 2015 Stock Option and Incentive Plan (the “Aytu 2015 Plan”) and the Neos Therapeutics, Inc. 2015 Stock Options and Incentive Plan (the “Neos 2015 Plan”, and collectively with the Aytu 2015 Plan, the “2015 Plans”). For the 2023 Equity Incentive Plan, the stockholders approved (a) 200,000 new shares, (b) 87,129 shares available for grant under the 2015 Plans be “rolled over” to the 2023 Equity Incentive Plan and (c) any shares that are returned to the company under the 2015 Plans be added to the 2023 Equity Incentive Plan. With the approval of the 2023 Equity Incentive Plan, no additional awards will be granted under the 2015 Plans. All outstanding awards previously granted under previous stock incentive plans will remain outstanding and subject to the terms of the plans. Stock options granted under the 2023 Equity Incentive Plan have contractual terms of 10 years or less from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards and restricted stock units have a vesting period of 3 to 4 years. As of December 31, 2023, the Company had 179,732 shares that are available for grant under the 2023 Equity Incentive Plan. Aytu 2015 Plan. On June 1, 2015, the Company’s stockholders approved the Aytu 2015 Plan, which, as amended in July 2017, provides for the award of stock options, stock appreciation rights, restricted stock and other equity awards for up to an aggregate of 150,000 shares of common stock. The shares of common stock underlying any awards that are forfeited, canceled, reacquired by Aytu prior to vesting, satisfied without any issuance of stock, expire or are otherwise terminated (other than by exercise) under the Aytu 2015 Plan will be added back to the shares of common stock available for issuance under the 2023 Equity Incentive Plan. On February 13, 2020, the Company’s stockholders approved an increase to 250,000 total shares of common stock in the Aytu 2015 Plan. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 3 to 4 years. The restricted stock awards have a vesting period ranging from 4 to 10 years, whereas the restricted stock units have a vesting period of 4 years. Neos 2015 Plan. Pursuant to the Neos Merger, the Company assumed 3,486 stock options and 1,786 restricted stock units previously granted under the Neos 2015 Plan. Accordingly, on April 19, 2021, the Company registered 5,272 shares of its common stock under the Neos 2015 Plan with the SEC. The terms and conditions of the assumed equity securities remained the same as they were previously under the Neos 2015 Plan. The Company allocated costs of the replacement awards attributable to pre-combination and post-combination service periods. The pre-combination service costs were included in the considerations transferred. The remaining costs attributable to the post-combination service period are being recognized as stock-based compensation expense over the remaining terms of the replacement awards. Stock options granted under this plan have contractual terms of 10 years from the grant date and a vesting period ranging from 1 to 4 years. Stock Options Stock option activity is as follows:
|  |  |  |  |  |  |  |  |  | Weighted |
|  |  |  |  |  |  |  |  |  | Average |
|  |  |  |  |  | Weighted |  |  | Remaining |
|  | Number of |  |  | Average |  |  | Contractual |
|  | Options |  |  | Exercise Price |  |  | Life in Years |
Outstanding June 30, 2023 |  |  | 52,762 |  |  | $ | 18.37 |  |  |  | 9.06 |
Granted |  |  | 112,000 |  |  | $ | 1.73 |  |  |  | 9.61 |
Forfeited/cancelled |  |  | (15,060 | ) |  | $ | 2.94 |  |  |  | — |
Expired |  |  | (615 | ) |  | $ | 184.80 |  |  |  | — |
Outstanding at December 31, 2023 |  |  | 149,087 |  |  | $ | 6.43 |  |  |  | 9.17 |
Exercisable at December 31, 2023 |  |  | 20,470 |  |  | $ | 30.18 |  |  |  | 8.02 |
The weighted-average grant date fair value of options granted during the six months ended December 31, 2023 was $1.73. As of December 31, 2023, there was $0.4 million total unrecognized compensation costs related to non-vested stock options granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.85 years. Restricted Stock Restricted stock activity is as follows:
|  |  |  |  |  | Weighted |
|  |  |  |  |  | Average Grant |
|  | Number of |  |  | Date Fair |
|  | Shares |  |  | Value |
Unvested at June 30, 2023 |  |  | 38,075 |  |  | $ | 142.20 |
Granted |  |  | 12,500 |  |  | $ | 1.77 |
Vested |  |  | (12,189 | ) |  | $ | 130.45 |
Forfeited/cancelled |  |  | (457 | ) |  | $ | 136.80 |
Unvested at December 31, 2023 |  |  | 37,929 |  |  | $ | 99.75 |
As of December 31, 2023, there was $2.0 million total unrecognized compensation costs related to non-vested restricted stock granted under the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.9 years. As of December 31, 2023, there was $0.3 million total unrecognized costs related to non-vested restricted stock outside of the Company’s equity incentive plan. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.1 years. As of December 31, 2023, 2,088 shares of restricted stock remain unvested. Restricted Stock Units Restricted stock units (“RSU” or “RSUs”) activity is as follows:
|  |  |  |  |  | Weighted |
|  |  |  |  |  | Average Grant |
|  | Number of |  |  | Date Fair |
|  | Shares |  |  | Value |
Unvested at June 30, 2023 |  |  | 4,963 |  |  | $ | 25.62 |
Vested |  |  | (1,126 | ) |  | $ | 24.28 |
Forfeited |  |  | (939 | ) |  | $ | 31.60 |
Unvested at December 31, 2023 |  |  | 2,898 |  |  | $ | 24.19 |
As of December 31, 2023, there was $0.1 million total unrecognized compensation costs related to non-vested RSUs granted under the Company’s equity incentive plans. The unrecognized compensation cost is expected to be recognized over a weighted average period of 1.2 years. Stock-based compensation expense related to the fair value of stock options, restricted stock, and RSUs was included in the consolidated statements of operations as set forth in the below table:
|  | Three Months Ended |  |  | Six Months Ended |
|  | December 31, |  |  | December 31, |
|  | 2023 |  |  | 2022 |  |  | 2023 |  |  | 2022 |
|  | (in thousands) |
Cost of sales |  | $ | 1 |  |  | $ | 3 |  |  | $ | 1 |  |  | $ | 8 |
Research and development |  |  | 2 |  |  |  | 14 |  |  |  | 3 |  |  |  | 23 |
Selling and marketing |  |  | — |  |  |  | 3 |  |  |  | — |  |  |  | 6 |
General and administrative |  |  | 817 |  |  |  | 3,047 |  |  |  | 1,746 |  |  |  | 4,207 |
Total stock-based compensation expense |  | $ | 820 |  |  | $ | 3,067 |  |  | $ | 1,750 |  |  | $ | 4,244 |

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org//718/tableOfContent Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration